Bioton's takeover of SciGen rebounds on its Q3 figures

Revenues dropped from zł.44.15 million to zł.34.31 million. According to Adam Wilczęga, president of Bioton, this was also due to taking over SciGen and consolidating its losses, but at the same time he assured the company was developing dynamically. "The fourth quarter will be the best in our history, in terms of financial results," said Wilczęga. After nine months of 2005 the net accumulated profit of the group amounted to zł.13 million, which is an increase from zł.8.7 million over the same period last year. Bioton's share of the national insulin market increased to 18.2% at the end of September as compared to just 8% at the end of 2004. (Parkiet, p. 4) M.M.